骨科手术患者的血栓预防;使用倾向得分匹配
Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is a common post-operative complication. The necessity for anticoagulant therapy after orthopedic surgeries is widely understood, but treatment administration patterns in the prevention of venous thromboembolism (VTE) after orthopedic surgeries during the hospital stay have yet to be examined.
The main objective of this study is to perform a comparative effectiveness review examining the benefits and harms associated with venous thromboembolism prophylaxis in patients undergoing orthopedic surgeries.
It is around efficacy and safety evaluation of using anticoagulant for thromboprophylaxis in patients undergoing orthopedic surgeries taking into the account the reliable selection of patients most benefit.
The aims of this study is to analyze patient records in teaching hospitals database of our country (including: Hanoi Medical University, Bach Mai Hospital, Cho Ray Hospital, Viet Duc University Hospital) and compare the outcomes and costs between different types of anticoagulant medications that were prescribed for the prevention of VTE following orthopedic surgeries. This analysis will assess and quantify the outcomes, resource utilization, and cost of care for patients receiving rivaroxaban or enoxaparin. The outcomes of interest include the occurence of DVT and PE, rates of major bleeds, medical resource utilization, and total costs (medical plus pharmacy).
研究概览
地位
地位
条件
条件
干预/治疗
干预/治疗
研究类型
研究类型
联系人和位置
学习地点
-
-
Hanoi
-
Hanoi、Hanoi、越南、10000
- Hanoi Medical University
-
-
参与标准
资格标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Patients aged 18 years or older who experienced a orthopedic surgeries during the hospitalization were the initial target population.
描述
Inclusion Criteria:
- Undergo Orthopedic Surgery
- Thromboprophylaxis Decision Taken
- At least 18 years of age
Exclusion Criteria:
- Planned intermittent pneumatic compression
- A requirement for anticoagulant therapy that could not be stopped
- Severe hypersensitivity reaction (eg, anaphylaxis) to rivaroxaban or enoxaparin.
- Received another anticoagulant for more than 24 hours
- Active bleeding or a high risk of bleeding
- Thrombocytopenia associated with a positive test for antiplatelet antibody.
- Warfarin associated international normalized ratio (INR) more than 1.5 on the day of the surgery
- Conditions preventing bilateral venography
- Intensive care unit (ICU) stay after surgery
- Pregnant or breast-feeding
- Creatinine clearance less than 30 ml per minute or acute renal failure before the surgery or at any point during the study period.
- Moderate or Severe (Child Pugh B or C) hepatic Impairment or in patients with any hepatic disease associated with coagulopathy.
- Concomitant use of drugs that are both P--glycoprotein inhibitors and moderate to strong cyp3a4 (ketoconazole, itraconazole, lopinavir/ritonavir, ritonavir, indinavir/ritonavir & conivaptan)
- Creatinine clearance (CrCl) 15 to 80 mL/min and concurrent use of P-glycoprotein inhibitors or moderate CYP3A4 inhibitors (eg, abiraterone acetate, diltiazem, dronedarone, erythromycin, verapamil)
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:RETROSPECTIVE
团体/队列数
队列和干预
团体/队列团体/队列 |
干预/治疗干预/治疗 |
|---|---|
|
Orthopedic surgery patient records
Medical records from patients aged 18 years or older with orthopedic surgeries during the hospitalization |
An oral anticoagulant medication for the prevention of VTE (Venous thromboembolism) related to orthopedic surgery. Patients received rivaroxaban during one day prior to or two days after orthopedic surgery during the hospitalization. An injectable anticoagulant medication for the prevention of VTE (Venous thromboembolism) related to orthopedic surgery. Patients received enoxaparin during one day prior to or two days after orthopedic surgeries during the hospitalization. |
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Deep-vein thrombosis (DVT)
大体时间:1 year
|
The frequency of Deep-vein thrombosis Symptoms and signs of DVT may include unilateral leg swelling, pain in the affected leg, calf tenderness in affected leg, increased leg warmth, erythema of affected leg, or a "palpable cord" may be felt in the affected leg. |
1 year
|
|
Non-fatal pulmonary embolism (PE)
大体时间:1 year
|
Frequency of pulmonary embolism (non-fatal) Regarding Pulmonary Embolism (PE), diagnosis is suspected in patients with dyspnea, tachypnea, pleuritic chest pain, cough, and/or fever. Diagnosis begins with initial risk stratification "Wells Clinical Model for Evaluating the Pretest Probability of pulmonary embolism (PE) " based on presence of shock or persistent hypotension to identify patients at high risk of early mortality. |
1 year
|
|
Mean length of hospital stay in days
大体时间:1 year
|
Length of hospital stay was obtained from the discharge record and was defined as the number of days from patient admission to the hospital for orthopaedic surgeries until discharge from the hospital. |
1 year
|
|
Total cost of care for index hospitalization in Vietnamese dong (VND)
大体时间:1 year
|
The mean total costs (medical plus pharmacy costs) from patient records in each antithrombotic cohort from the index hospitalization |
1 year
|
|
Death
大体时间:1 year
|
Death from any cause including venous thromboembolism |
1 year
|
次要结果测量
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Major bleeding risk
大体时间:After 4 hours of the first dose and up to 2 days after the last dose of the study drug
|
The incidence of major bleeding beginning after the first dose of the study drug and up to 2 days after the last dose of the study drug (on-treatment period). Major bleeding is defined as bleeding that is fatal, occurs in a critical organ (e.g., retroperitoneal, intracranial, intraocular, and intraspinal bleeding), or requires reoperation or extra surgical-site bleeding that was clinically overt and is associated with a fall in the hemoglobin level of at least 2 g per deciliter or that requires transfusion of 2 or more units of whole blood or packed cells. |
After 4 hours of the first dose and up to 2 days after the last dose of the study drug
|
|
Other on-treatment bleeding
大体时间:After 4 hours of the first dose and up to 2 days after the last dose of the study drug
|
The incidence of major bleeding beginning after the first dose of the study drug and up to 2 days after the last dose of the study drug (on-treatment period). Major bleeding is defined as bleeding that is fatal, occurs in a critical organ (e.g., retroperitoneal, intracranial, intraocular, and intraspinal bleeding), or requires reoperation or extra surgical-site bleeding that was clinically overt and is associated with a fall in the hemoglobin level of at least 2 g per deciliter or that requires transfusion of 2 or more units of whole blood or packed cells. |
After 4 hours of the first dose and up to 2 days after the last dose of the study drug
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
学习开始
初级完成 (估计的)
初级完成
研究完成 (估计的)
研究完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (实际的)
首次发布
研究记录更新
最后更新发布 (实际的)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
其他研究编号
- ĐTĐL.CN.53/16
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 共享支持信息类型
- 研究方案
- 树液
- 国际碳纤维联合会
- 分析代码
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.